title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Availability of data and materials | The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request. | PMC10240679 | ||
Declarations | PMC10240679 | |||
Ethics approval consent to participate | The ethical review board of Fayoum University Hospital approved the study design before the start of the study (M 546). The methods were done according to the relevant guidelines and regulations. Written informed consent was obtained from all patients. | PMC10240679 | ||
Consent for publication | Written informed consent was obtained from all patients. | PMC10240679 | ||
Competing interests | The authors declare no competing interests. | PMC10240679 | ||
References | PMC10240679 | |||
Subject terms | IgAN, proteinuria | IGA NEPHROPATHY | We sought to evaluate the efficacy and safety of budesonide (Budenofalk) in the treatment of patients with IgA Nephropathy. We conducted a prospective, interventional, open-label, single-arm, non-randomized study that enrolled 32 patients with IgAN at high risk of progression (BUDIGAN study, ISRCTN47722295, date of reg... | PMC10656480 |
Introduction | IgAN, primary glomerular disease | PATHOGENESIS, IMMUNOGLOBULIN A NEPHROPATHY | Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease worldwideThe efficacy of immunosuppression in the management of IgAN remains highly controversialThe gut-kidney axis hypothesis has been supported by several studies over the past decades to underlie the pathogenesis of IgANAccordingly, w... | PMC10656480 |
Material and methods | PMC10656480 | |||
Study design and population | IgAN, proteinuria, primary IgAN | The BUDIGAN study (ISRCTN47722295, date of registration 14/02/2020) is a prospective, interventional, open-label, non-randomized study that enrolled 32 patients with IgAN, at high risk of progression. The study design is in line with our previous reportThe inclusion criteria were: age ≥ 18 years, patients with a histol... | PMC10656480 | |
Treatment | proteinuria | All patients had received a stable dose of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy for a period of at least 3 months prior to budesonide initiation. The dose of ACEI/ARB was titrated to a maximum tolerated dose in order to achieve a target blood pressure (BP) of 12... | PMC10656480 | |
Study follow-up and data collection | The study follow-up period was 36 months. At baseline the following data were collected: age, gender, mean arterial pressure, renal function assessed by serum creatinine and eGFR (estimated glomerular filtration rate calculated by the 2009 CKD-EPI equation | PMC10656480 | ||
Study outcomes | proteinuria | ADVERSE EVENTS | The efficacy study outcomes were the effects of Budenofalk on proteinuria and eGFR at 12, 24 and 36 months. The safety outcomes were treatment emergent adverse events. | PMC10656480 |
Statistical analysis | ± | Continuous variables were expressed as either mean (± standard deviation or 95% confidence interval) or median (interquartile range, IQR: 25th–75th percentiles) and categorical variables as percentages. Differences between groups were assessed in case of continuous variables by Student Statistical analyses were perform... | PMC10656480 | |
Results | PMC10656480 | |||
Adverse events | gastro-intestinal bleeding, osteonecrosis | OSTEONECROSIS, ADVERSE EVENT, DIABETES MELLITUS, BLOOD, ARTERIAL HYPERTENSION | Overall, the 24-month treatment with budesonide was well tolerated (Table Adverse events.In addition, there were no patients with new-onset diabetes mellitus, gastro-intestinal bleeding, osteonecrosis or worsening of preexisting arterial hypertension. The blood glucose levels and mean arterial pressures remained stable... | PMC10656480 |
Author contributions | Concept/design: all authors. Data analysis/interpretation: B.O., G.I. Statistics: B.O. Data collection: all authors. Drafting article: B.O, G.I. Critical revision of article: all authors. Approval of article: G.I. | PMC10656480 | ||
Data availability | All data generated or analyzed during this study are included in this published article. | PMC10656480 | ||
Competing interests | The authors declare no competing interests. | PMC10656480 | ||
References | PMC10656480 | |||
Background | cancer | CANCER, SECONDARY | There is substantial heterogeneity in symptom management provided to pediatric patients with cancer. The primary objective was to describe the adaptation process and specific adaptation decisions related to symptom management care pathways based on clinical practice guidelines. The secondary objective evaluated if inst... | PMC10108500 |
Methods | Fourteen previously developed symptom management care pathway templates were reviewed by an institutional adaptation team composed of two clinicians at each of 10 institutions. They worked through each statement for all care pathway templates sequentially. The institutional adaptation team made the decision to adopt, a... | PMC10108500 | ||
Results | Initial care pathway adaptation decision making was completed over a median of 4.2 (interquartile range 2.0-5.3) weeks per institution. Across all institutions and among 1350 statements, 551 (40.8%) were adopted, 657 (48.7%) were adapted, 86 (6.4%) were rejected and 56 (4.1%) were no longer applicable because of a prev... | PMC10108500 | ||
Conclusions | Acceptability of the 14 care pathways was evident by most statements being adopted or adapted. The adaptation process was accomplished over a relatively short timeframe. Future work should focus on evaluation of care pathway compliance and determination of the impact of care pathway-consistent care on patient outcomes. | PMC10108500 | ||
Trial registration | clinicaltrials.gov, NCT04614662. Registered 04/11/2020, | PMC10108500 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12885-023-10835-0. | PMC10108500 | ||
Keywords | PMC10108500 | |||
Background | cancer [, toxicities, cancer- | Supportive care for pediatric oncology patients focuses on preventing and managing cancer- and treatment-related toxicities. Early assessment and intervention for these toxicities are important as they are associated with morbidity, reduced quality of life, increased healthcare utilization and treatment-related mortali... | PMC10108500 | |
Methods | The study was approved by the Research Ethics Board of The Hospital for Sick Children (SickKids), the Western Institutional Review Board and the Institutional Review Boards of each participating institution. For patient participation in the trial, informed written consent was obtained from participants and from the par... | PMC10108500 | ||
Development of symptom management care pathway templates | cancer | CANCER, PEDIATRIC CANCER | This study was focused on the management of the 15 symptoms captured by the Symptom Screening in Pediatrics Tool (SSPedi). SSPedi is a reliable, valid and responsive self-report symptom assessment tool for English, French and Spanish-speaking children and adolescents 8–18 years of age receiving cancer treatments [The a... | PMC10108500 |
Institutional adaptation of symptom management care pathway templates | Fig.
Phases Required to Adapt the 14 Care Pathway Templates at Each of the 10 Institutions
For each statement, the institutional adaptation team made the decision to adopt, adapt or reject the statement regardless of whether the source CPG recommendation was strong or conditional. For statements stemming from condit... | PMC10108500 | ||
Survey of institutional characteristics | The creation, distribution and results of the baseline survey have previously been described [In addition to these characteristics, we administered the Consolidated Framework for Implementation Research (CFIR) to help understand factors associated with care pathway adaptation decisions [ | PMC10108500 | ||
Statistics | SECONDARY | The primary aim was descriptive. The secondary aim evaluated the adaptation decision made for each of the statements on the symptom management care pathway templates and did not include new statements added by the institution. This outcome was dichotomized as reject vs. did not reject for each statement. The institutio... | PMC10108500 | |
Results | nausea, anger, vomiting, pain, mucositis | MUCOSITIS | Table
Characteristics of Institutions (N = 10)Abbreviation: IQR - interquartile rangeFigure Table
Distribution of Statements and Adaptation Choices across 10 Institutions (N = 1350 Statements*)* Denominator for adaptation choice was the number of statements on the template care pathways (N = 1350); new statements add... | PMC10108500 |
Discussion | PEDIATRIC CANCER | We created 14 pediatric cancer symptom management care pathway templates based on CPGs and developed a process to adapt them at 10 institutions. We found that most care pathway statements were adopted or adapted, with 6.4% of statements being rejected. Most commonly, the reason for statement rejection was not agreeing ... | PMC10108500 | |
Conclusions | In conclusion, acceptability of the 14 care pathways was evident by most statements being adopted or adapted. The adaptation process for 14 care pathways was accomplished in a relatively short timeframe, with a median time to accomplish the initial care pathway adaptation decision-making phase over 4.2 weeks per instit... | PMC10108500 | ||
Acknowledgements | We would like to thank the following co-leaders of the institutional adaptation teams for their work in adapting the care pathways: Nkechi Mba MD, Alexis Lemke RN, Claudette Vicks RN, Cherie Hadley RN, Andrew Cluster MD, Marissa Henning PharmD, Allison Bechtel MD, Dee Ann Omatsu NP and Nelda Itzep MD. We would also lik... | PMC10108500 | ||
Author contributions | LLD, MR | EV, FS, AK, LY, CA, CB, VA, RN, KK, DF, EO, SB, WK, MR, LLD, LS participated in all phases of the Institutional Adaptation of Symptom Management Care Pathway Templates. EV, LK, MB, AG, GT, LLD and LS were involved in material design and procedures. LS drafted the manuscript, all authors reviewed, revised and approved t... | PMC10108500 | |
Funding | ONCOLOGY | LS is supported by the Canada Research Chair in Pediatric Oncology Supportive Care. The study was supported by operating grants from the Canadian Institutes of Health Research (PJT 169165) and the National Institutes of Health (1R01CA251112). | PMC10108500 | |
Data availability | The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. | PMC10108500 | ||
Declarations | PMC10108500 | |||
Ethics approval and consent to participate | The study was approved by the Research Ethics Board of The Hospital for Sick Children (SickKids), the Western Institutional Review Board and the Institutional Review Boards of each participating institution. All research was performed in accordance with the Declaration of Helsinki. Agreement to be an institutional adap... | PMC10108500 | ||
Consent for publication | Not applicable. | PMC10108500 | ||
Competing interest | The authors declare that they have no competing interests. | PMC10108500 | ||
Abbreviations | Clinical practice guidelineSupportive care Prioritization, Assessment and Recommendations for KidsSymptom Screening in Pediatrics ToolConsolidated Framework for Implementation ResearchInterquartile range | PMC10108500 | ||
References | PMC10108500 | |||
Abstract | ADHESION | Editor: Linda WangAssociate Editor: Karin Hermana NepplenbroekConflicts of InterestThe authors declare no competing interests.Periodontal regeneration faces multiple challenges, the most important being cellular insufficiency. In an attempt to improve defect cellularity, we aimed to demonstrate enhancing cellular attra... | PMC10786453 | |
Methodology | periodontitis, PD | PERIODONTITIS, SECONDARY, PLAQUE | Forty-five intrabony defects were selected from patients with stage III or IV - grade A or B periodontitis and divided randomly into three equal groups of 15 each: group1 (G1): received minimally invasive surgical technique (MIST) alone, group2 (G2): received MIST and placebo hydrogel injection, and group3 (G3): were ... | PMC10786453 |
Results | PD | Significant improvements in DBF, CAL, and PD were observed in the three studied groups 6 months following therapy compared to baseline (p<0.05). A significant improvement in DBF was reported in G3 compared to G1 and 2 (p=0.005). Additionally, a significantly higher CAL gain was reported in G3 compared to that of G1 (p... | PMC10786453 | |
Conclusion | RGD peptide carried on a hydrogel delivery agent and contained with a minimally invasive flap could be a reliable option in improving the outcomes of periodontal therapy. | PMC10786453 | ||
Introduction | ADHESION, RECRUITMENT | Periodontal regeneration is a complex process that involves coordinated activities and interactions of many cell types, extracellular matrix, cytokines, and specific growth factors to restore tissue integrity. The most important challenge facing periodontal regeneration is cellular insufficiency.Apoptosis is initiated ... | PMC10786453 | |
Methodology | PMC10786453 | |||
Population | MAY | This randomized double-blinded controlled clinical trial included 45 patients, each contributing with one periodontal intrabony defect. Patients were selected from the Medicine, Oral Diagnosis, & Periodontology Department of the Faculty of Dentistry, Minia University outpatient clinic from May 2020 to December 2021. Th... | PMC10786453 | |
Inclusion and exclusion criteria | PERIODONTITIS | Patients were included based on the following criteria: 1- Medically free, from both sexes, and in the age range of 20-55 years old. 2- Stage III or IV, grade A or B periodontitis. | PMC10786453 | |
Randomization, allocation, and blinding | Participants were randomly assigned using a computerized random number generator (Available from: www.random.org) into three parallel groups, with 15 participants each. Group 1: intrabony defect sites underwent MIST alone. Group 2: underwent MIST and placebo hydrogel injections. Group 3: underwent MIST and RGD hydrogel... | PMC10786453 | ||
Consort diagram for the study | PMC10786453 | |||
Sample size calculation | Power analysis was designed to have appropriate power to apply a statistical test of the null hypothesis, which implied that no difference would be found in bone healing between different groups. By adopting an alpha level of (0.05) a beta of (0.2), i.e., power=80% and an effect size (f) of (0.479), calculated based on... | PMC10786453 | ||
Interventions | PMC10786453 | |||
Hydrogel preparation | A total of 50 mg of Carbopol® 940 (Lubrizol Corporation, US) was impregnated in 10 ml water, remaining under a magnetic stirrer until completely dissolved. pH and viscosity were adjusted with triethanolamine (TEA) until the required viscosity was approximately reached (40,000–60,000 mPa-s). | PMC10786453 | ||
Preparation of 2.5 mM RGD | A total of 10 mg of RGD | PMC10786453 | ||
Pre-surgical preparation | bleeding | BLEEDING, PLAQUE | Supra and subgingival instrumentation were performed using a universal curette and ultrasonic instrument (woodpecker U600, KMC). Pre-surgical preparation was performed following the EFP S3 guidelines.20 Step 1: full mouth supragingival scaling in one visit together with patient education and oral hygiene instructions. ... | PMC10786453 |
Outcome measures | SECONDARY | Clinical and radiographic parameters were obtained four weeks after (S2) Phase 1 therapy was completed (baseline) and six months after surgery. The primary outcome was the evaluation of clinical attachment level (CAL), defect base fill (DBF), crestal bone level (CBL), and defect width (DW). The secondary outcomes were ... | PMC10786453 | |
(A) MIST for 2-wall intrabony defect incision; (B) RGD loaded hydrogel application; (C) baseline radiographic measures of CEJ-BD= 9.10 mm; (D) radiographic width of bone defect= 2.3 mm; (E) radiographic measures of CEJ-BC= 4.44 mm; (F) defect angle= 39.44° | PD | Probing Depth (PD): measurements were recorded by UNCBiochemical evaluation: Gingival Crevicular Fluid (GCF) samples were collected by paper point size 30 (META BIOMED | PMC10786453 | |
Surgical intervention | Selected sites were anesthetized using articaine HCl 4% with adrenaline (1:100,000) (Artinibsa, inibsaSpain, wedjat pharma). A minimally invasive surgical flap was performed as described by Cortellini and Tonetti | PMC10786453 | ||
Data analysis | Numerical data were presented as mean and standard deviation values. They were tested for normality using Shapiro-Wilk’s test. PI and GI were non-parametric and were analyzed using Kruskal-Wallis test. Radiographic changes in bone defect (CEJ-BD, crestal bone level, and defect width) were statistically analyzed by pair... | PMC10786453 | ||
Results | PMC10786453 | |||
Study population | In this double-blinded randomized clinical trial, 45 patients were enrolled and divided into three groups, all patients bone loss/ age were calculated to be ≤ 1. Group 1, MIST alone, was performed for 15 sites (8 males and 7 females with a mean age of 34.80±7.07); Group 2, MIST + placebo hydrogel applied in 15 sites (5... | PMC10786453 | ||
Demographic characteristics | PMC10786453 | |||
Radiographic outcomes (primary outcomes) | Significant differences between baseline and 6-month measurements of DBF were observed in all groups (
| PMC10786453 | ||
Radiographic measures after 6 months follow up. (A) defect bone fill after 6 months= 4.69 mm; (B) defect width= 1.69 mm; (C) crestal bone formation= 2.31 mm; (D) angle measure= 29.14° | PMC10786453 | |||
Plaque index and gingival index | After six months, no significant differences were reported for GI and PI scores. The PI mean was reported to be (0.4±0.7) in Group 1 and (0.4±0.52 and 0.4±0.52) in Groups 2 and 3, respectively. There was no statistically significant difference between baseline and 6-month follow-up between the three groups (p > 0.05) a... | PMC10786453 | ||
Mean PI and GI data at baseline and 6 month evaluation periods | PMC10786453 | |||
Clinical attachment Level and pocket depth outcomes | Clinical attachment level and pocket depth showed a significant reduction from baseline to 6-month measurements in the three studied groups (p value= 0.000*). In G1 mean CAL reduced from 8.9±0.99 to 4.3±0.95, group 2 from 8.8±1.48 to 4.1±0.74 and in G3 from 9.5±1.08 to 3.5±0.53. A statistically significant higher reduc... | PMC10786453 | ||
Changes in clinical and radiographic parameters over time and comparisons between groups | PMC10786453 | |||
Biochemical outcomes of BMP-2 release profile | Gingival crevicular fluid BMP-2 levels showed a significant increase in its level throughout the selected evaluation periods in all groups. In G1, there was an increase from a mean of 223.85±7.27 on day 1, to 307.64±16.98 on day 7 and 333.15±31.62 on day 14, reaching the optimum level on day 21 with a mean level of 358... | PMC10786453 | ||
Changes in BMP-2 - intragroup comparisons and comparisons between groups over time | PMC10786453 | |||
Discussion | necrosis | BLOOD CLOT, ADHESION, COLLAPSE, NECROSIS, CREST | The main three elements required for optimal regeneration are defect stability, space maintenance, and enhanced cellular and mediators’ availability. The present study suggested a combination of MIST—supposed to provide reliable defect stability, space maintenance, and growth factors containment—with RGD adhesion prote... | PMC10786453 |
Conclusion | ADHESION | Within the limitations of this study, which, to the best of our knowledge, is the first study that evaluated the clinical and biochemical significance of RGD hydrogel in periodontal regeneration, we can conclude that the use of RGD peptide-loaded hydrogel could be an effective treatment option that improved periodontal... | PMC10786453 | |
Acknowledgment | Thanks to Prof. Dr. Usama Farghaly, professor of Pharmaceutics, Faculty of Pharmacy, Minia University, for his cooperation, time, and patience throughout this work.Data availability statementAll data generated and analyzed during this study are included in this published article. | PMC10786453 | ||
References | PMC10786453 | |||
Subject terms | tumor, tumors, RAS-mutant unresectable, CRC | METASTATIC COLORECTAL CANCER, SECONDARY, TUMORS, TUMOR | Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from immune checkpoint blockade, chemotherapy with targeted therapies remains the only therapeutic option for microsatellite stable (MSS) tumors. The single-arm, phase 1b/2 MEDITREME trial evaluated the safety and efficacy of durv... | PMC10427431 |
Main | CRC | METASTATIC COLORECTAL CANCER, METASTASES, INFILTRATES | Treatment of metastatic colorectal cancer (CRC) relies mainly on chemotherapy, generally for palliative purposes when metastases cannot be removed. Median overall survival (OS) of CRC has been rising with improvements in chemotherapeutic and targeted therapiesMany studies have underlined that the immune system recogniz... | PMC10427431 |
Results | PMC10427431 | |||
Patient characteristics | unresectable metastatic RAS-mutated CRC | Overall, 57 patients with unresectable metastatic RAS-mutated CRC were included from eight French hospitals between 30 August 2017 and 20 December 2019 (Extended Data Fig. | PMC10427431 | |
Feasibility and safety | ADVERSE EVENT | Adverse events (AEs) occurred in 56 (98%) patients (Extended Data Table | PMC10427431 | |
Efficacy analyses | tumors | SECONDARY, TUMORS | Among the 57 patients, MSS status was known for 51 patients; three had MSI status; and 48 had MSS status. Only the 48 patients with MSS tumors were included in the eligible population for efficacy analyses, per protocol. Median follow-up was 36 months (2.5–33.9). The primary objective of phase 2 was met, with 3-month P... | PMC10427431 |
Exploratory analysis of genomic correlates | NRAS | APC | Somatic panel to confirm NRAS, KRAS and BRAF mutation and MSI status was performed for all patients. Exome sequencing was performed in 37 patients. The most frequent mutations were APC, KRAS and TP53 (Fig. | PMC10427431 |
Exploratory analysis of transcriptome correlates | RNA sequencing (RNA-seq) analysis was performed for 36 patients. The relationships between median PFS and expression of individual protein-coding genes were tested using differential gene analysis. Using ssGSEA, EMT signature, IL6/JAK/STAT3 signature and CAF signature showed a borderline relationship with shorter PFS, ... | PMC10427431 | ||
Exploratory analysis of immunological correlates | CPS | PD-L1 CPS expression was not related to outcome (Extended Data Fig. | PMC10427431 | |
Analysis of in situ tumor-specific CD8 response in responders | LIVER METASTASES | Among patients with partial response, one patient who underwent resection of remaining liver metastases was monitored using single-cell RNA sequencing (scRNA-seq) and T cell receptor (TCR) sequencing. PBMCs were taken at baseline, at 1 month and at the time of liver surgery. Tumor-infiltrated lymphocytes (TILs) were is... | PMC10427431 | |
Discussion | AtezoTRIBE, tumor, death, CRC, RAS-mutated, MSS, tumors | TUMOR, INFILTRATION, LIVER METASTASES, INFILTRATE, MUTANT, TUMORS | This study reports clinical and biological response with first-line chemo-immunotherapy for RAS-mutated metastatic CRC. This study reached its primary objective, with 3-month PFS of 90.7%, 6-month PFS of 60% and median PFS of 8.2 months, whereas the expected median PFS for such a population is 5–6 months with FOLFOX al... | PMC10427431 |
Methods | PMC10427431 | |||
Trial registration | The ‘Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined with FOLFOX in mCRC (MEDITREME)’ trial was prospectively registered with ClinicalTrials.gov identifier | PMC10427431 | ||
Inclusion and ethics | RAS-mutated | The protocol was approved by the Ethics Committee CPP TOURS – Région Centre – Ouest 1 on 27 March 2017 under the number 2017T1-03 and was registered with the French national health products agency (ANSM). The French ethical authorities asked us to include only RAS-mutated metastatic CRC because RAS WT patients must rec... | PMC10427431 | |
Patient selection | Patients were enrolled in eight hospitals in France (Georges-François Leclerc Anticancer Center, UNICANCER, Dijon; Hôpital Franco-Britannique – Fondation Cognacq-Jay, Levallois-Perret; CHU, Nantes; CHU, Besançon; Clinique CARIO, Plérin; Saint Antoine, Hospital, Paris; Institut Bergonie, Bordeaux; and Pompidou Hospital,... | PMC10427431 | ||
Inclusion criteria | Reccurence, Cancer | ADVERSE EVENT, METASTASIS, LIVER METASTASES, ONCOLOGY, CANCER |
Written informed consent and any locally required authorization obtained from the patient before performing any protocol-related procedures, including screening evaluationsMale or female age ≥18 years at time of study entryPerformance status of 0 or 1 according to the Eastern Cooperative Oncology Group and World Healt... | PMC10427431 |
Exclusion criteria | vitiligo, tumor, bleeding, malignancy, non-melanoma skin cancer, allergy, Crohn’s disease, psychiatric, autoimmune disease, toxicity, ischemia, psoriasis, hemoptysis, rest limb claudication or, comorbidity, gastritis, infection, hypotension, peptic ulcer disease, lentigo maligna, hypersensitivity, myocardial infarction... | VITILIGO, THIRD DEGREE HEART BLOCK, TUMOR, RECURRENCE, BLEEDING, CARDIOVASCULAR DISEASE, INFLAMMATORY BOWEL DISEASE, SYMPTOMATIC CONGESTIVE HEART FAILURE, ALLERGY, CARDIAC ARRHYTHMIA, LUNG METASTASES, CARCINOMA IN SITU, AUTOIMMUNE DISEASE, MOBITZ II, ISCHEMIA, PSORIASIS, GASTRITIS, BRAIN METASTASES, ULCERATIVE, INFECTI... |
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). Previous enrollment in the present study.Participation in another clinical study with an investigational product during the last 4 weeksAny previous treatment with a PD-1 or PD-L1/CTLA-4 inhibito... | PMC10427431 |
Study design and statistical hypothesis | colorectal MSI disease, colorectal MSS, MSS disease, colorectal MSS disease | DISEASE, SECONDARY | This was a multicenter, single-arm, open-label, phase 1/2 study. The study was performed in two steps (Extended Data Fig. The primary objective of step 2 was to determine efficacy of the combination of durvalumab (anti-PD-L1) + tremelimumab (anti-CTLA-4) + mFOLFOX6 in terms of PFS in patients with colorectal MSS diseas... | PMC10427431 |
Procedures | tumor, Tumor, Cancer | DISEASE PROGRESSION, TUMOR, TUMOR, DISEASE, BLOOD, CANCER | Patients received first-line induction with mFOLFOX6 consisting of an intravenous infusionClinical data were collected at the Department of Statistics of the Centre Georges-François Leclerc. Tumor assessments were based on investigator-reported measurements and were performed according to RECIST version 1.1 and repeate... | PMC10427431 |
Plasma collection | After the blood sampling was done at the different times described above, a heparin tube was used to isolate and bank the plasma. For this purpose, after collection, the heparin tube was centrifuged at 1,000 | PMC10427431 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.